Cartesian Therapeutics, Inc. Common Stock (RNAC) is a publicly traded Healthcare sector company. As of September 21, 2026, RNAC trades at $7.97 with a market cap of $242.95M and a P/E ratio of -1.60. RNAC moved -2.05% today. Year to date, RNAC is +11.37%; over the trailing twelve months it is -22.11%. Its 52-week range spans $5.60 to $20.00. Analyst consensus is strong buy with an average price target of $32.60. Rallies surfaces RNAC's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks the latest RNAC news, catalysts, market updates, source links, and AI summaries when news is available.
| Metric | Value |
|---|---|
| Price | $7.97 |
| Market Cap | $242.95M |
| P/E Ratio | -1.60 |
| EPS | $-5.02 |
| Dividend Yield | 0.00% |
| 52-Week High | $20.00 |
| 52-Week Low | $5.60 |
| Volume | 14.98K |
| Avg Volume | 0 |
| Revenue (TTM) | $2.80M |
| Net Income | $-130.30M |
| Gross Margin | 0.00% |
6 analysts cover RNAC: 0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $32.60.